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1 Additional differences arise from multigenic and eMotivation: Genetic factors determine differences in pharmacokinetics, drug efﬁcacy, and drug responses
between individuals and sub-populations. Wrong dosages of drugs can lead to severe adverse drug reac-
tions in individuals whose drug metabolism drastically differs from the ‘‘assumed average’’. Databases
such as PharmGKB are excellent sources of pharmacogenetic information on enzymes, genetic variants,
and drug response affected by changes in enzymatic activity. Here, we seek to aid researchers, database
curators, and clinicians in their search for relevant information by automatically extracting these data
from literature.
Approach: We automatically populate a repository of information on genetic variants, relations to drugs,
occurrence in sub-populations, and associations with disease. We mine textual data from PubMed
abstracts to discover such genotype–phenotype associations, focusing on SNPs that can be associated
with variations in drug response. The overall repository covers relations found between genes, variants,
alleles, drugs, diseases, adverse drug reactions, populations, and allele frequencies. We cross-reference
these data to EntrezGene, PharmGKB, PubChem, and others.
Results: The performance regarding entity recognition and relation extraction yields a precision of
90–92% for the major entity types (gene, drug, disease), and 76–84% for relations involving these types.
Comparison of our repository to PharmGKB reveals a coverage of 93% of gene–drug associations in
PharmGKB and 97% of the gene–variant mappings based on 180,000 PubMed abstracts.
Availability: http://bioai4core.fulton.asu.edu/snpshot.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Genetic factors determine differences in pharmacokinetics,
drug efﬁcacy, and drug responses between individuals and sub-
populations. A large proportion of such differences is attributable
to single nucleotide polymorphisms (SNPs)1 in drug metabolizing
enzymes, drug transporters, drug receptors, and ion channels. An
example is the drug-metabolizing enzyme CYP2D6 with more than
70 known allelic variations, at least 15 of which encode for a non-
functional enzyme (null allele) [1]. Hepatic metabolism of many
prescription drugs, such as anti-depressants and beta-AR receptor
blockers, is (partially) dependent on CYP2D6 activity. Patients char-
acterized as poor metabolizers (null allele or decreased activity) may
retain high plasma concentrations of the administered drug whenll rights reserved.
., Pharma Research and Early
J 07110, USA.
enberg).
nvironmental factors.they are treated with typical dosages, and develop side effects. On
the other hand, rapid metabolizers, with a highly efﬁcient variant of
the enzyme and thus a high rate of drug metabolism, may not reach
the therapeutically required plasma level—or conversely, reach a
toxic level of the drug’s metabolites2 [2].
Determining each individual patient’s metabolic capacity3 thus
is an important step towards determining the optimal dosage when
moving beyond the still common ‘‘one-dose-suits-all’’ approach. The
following examples shall explain some of the effects of wrong dos-
ages. Wuttke et al. [1] presented a survey of 1200 patients treated
with metoprolol (for coronary artery disease, chronic heart failure,
hypertension) and exhibiting adverse drug reactions. Poor metabo-
lizers had a ﬁvefold higher risk for development of adverse drug2 As is the case, for instance, with ultra-rapid metabolizers of codeine, where its
bstrate morphine cannot be cleared as fast, resulting in narcosis and apnae.
3 Here: phenotype determination with respect to drug response. Phenotypes for the
urpose of this study are clinical symptoms; we exclude molecular phenotypes suchsu
p
as gene expression for now.
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one, even leading to severe effects. Kirchheiner et al. [3] performed
an extensive literature survey on 32 anti-depressants to ﬁnd sub-
population-speciﬁc dosage recommendations, covering 54 studies.
Focusing on the cytochrome p450 enzymes CYP2D6 and CYP2C19,
they distinguished between poor, intermediate, rapid, and ultra-ra-
pid metabolizers. Depending on the drug, Kirchheiner et al. found
recommended dosages ranging from only 20% of the ‘usual’ dosage
for poor metabolizers to 140% for ultra-rapid metabolizers. Lazarou
et al. [4] found that 6.7% of hospitalized patients would develop se-
vere ADRs, with 0.3% fatal reactions, resulting in around 100,000
deaths per year in the US.4
One aim of pharmacogenetics is to correlate genetic ﬁngerprints
to probable drug responses, thus helping to select the most efﬁ-
cient drug and give dosage recommendations. Such information
on SNPs, their effect on enzymatic activity, their frequencies in
populations, and related data, are spread across a large number
of clinical studies and surveys. PharmGKB collects information
‘‘about the impact of human genetic variations on drug response,’’
currently listing around 2400 human genetic variants from more
than 3,500 articles [5]. All data were curated via literature review
and can be searched by gene, drug, disease, etc. PubMed indexes
close to 100,000 articles for the query ‘‘(drug OR treatment)
AND metabolism AND (allele OR variant OR mutation)’’
alone. This later fact hints at a large number published data about
genetic variations and pharmacokinetic and -dynamic phenotypes
still to be indexed. Altman and Klein [6] suggested related
opportunities to unveil pharmacokinetic, pharmacodynamic, and
pharmacogenomic associations by mining the literature and inte-
grating them with existing databases and results from other bioin-
formatics methods.
In this paper, we address the issue of automatically extracting
information on genetic variations and their implications for drug re-
sponses from PubMed abstracts. We concentrate on clinical/patho-
logical symptoms as phenotypes in this paper, and exclude
molecular phenotypes such as gene expression and RNAi. We seek
to enrich these former correlations with information on diseases,
mutations, RefSNPs (rs-numbers), alleles, and their population-spe-
ciﬁc frequencies. Here, our focus is on ﬁnding data relating genes to
drugs to diseases, and providing information on genetic variants,
allele names, and/or RefSNPs for each gene in a relation; we add
frequencies and populations pertaining to observed genotypes/
haplotypes whenever possible. From an application-oriented, phar-
macogenetics perspective, wewant to provide a repository covering
all this information, helping database curators to search and incor-
porate relevant information, guiding clinicians in their decisions to
administer which drugs in which dosages, and aiding drug develop-
ers in their studies. Thus, we are trying to help establish the ‘‘shift
from population-based data toward personal health care’’ [7]. From
a practical, text mining perspective, we want to study how one can
effectively put together a text mining system for a more complex
task, possibly using existing tools; and what to expect regarding
effort, efﬁciency, and performance.
1.1. Related work
In work related to ours, Wang et al. [8] recently conducted a fea-
sibility study on mining literature for pharmacokinetics (PK)
numerical data. They searched for PK parameters AUC, half-life,
bio-availability, clearance, dose, and administration route (oral
vs. intravenous), as well as subject type (sex, age, ethnicity). For
selecting abstracts relevant to the drug midazolam, they achieved
an f-score between 68% and 78%; for midazolam clearance data,4 Meta-analysis of 39 studies from 1998 and older. 5 DiDB—see http://www.druginteractioninfo.org/.they achieved an f-score of 90% from 41 relevant abstracts. Overall,
for seven different drugs, literature mining generated up to 4-fold
higher information content on clearance data as compared to the
DiDB database.5
The method presented by Theobald and colleagues starts with a
set of known relations between genes, drugs, and diseases to gen-
erate Bayesian networks [9]. Conditional probabilities were gener-
ated using co-occurrence statistics of these relations gathered from
all of PubMed. Overall, Theobald et al. found data on 1730 gene/
drug/disease relations that were contained in PharmGKB to build
this network. In the end, one can analyze the network to ﬁnd
hypotheses on drug mechanisms, biomarkers for treatment, or
markers of genetic diseases.
Doughty et al. presented a study in which they map mutations
to diseases, namely forms of prostate and breast cancer [10]. Muta-
tions were extracted based on a set of regular expressions,
wrapped in the ‘‘extractor of mutations’’ (EMU) tool [10]; to recog-
nize gene names, a gazetteer lookup based on HUGO and NCBI was
developed; and MetaMap [11] was employed after narrowing its
UMLS vocabulary down to concepts denoting forms of prostate
and breast cancer, respectively. The authors evaluated three types
of extracted data (mutations, mutations mapped to genes, and
gene + mutation + disease associations). EMU extracted mutations
with a precision of 94–97%; initial mapping of mutations to genes
achieved a precision of 42–53%; after a ﬁltering steps that cross-
checked the predicted gene’s sequence with the mutation (residue
found at given position in the sequence), EMU’s precision reached
74–80%. Associating mutations with genes with diseases yielded a
precision of 55–77% after ﬁltering. Doughty et al. [10] cross-
checked their extracted associations with OMIM, dbSNP, and
SwissProt, showing that, for instance, 86 out of 144 breast can-
cer-related mutations were not yet contained in OMIM.
Lauria and coworkers presented a rule-based approach to ex-
tract mutations and map them to impacts on protein properties,
such as function, stability, and enzyme kinetics [12]. For recogni-
tion ofmutations and theirmapping to canonical forms, the authors
utilized MutationFinder [13]. Grounding mutations to protein se-
quences started with candidate proteins extracted from the entire
document the mutation occurred in. In a ﬁltering step, residues
and positions involved were compared to the candidates’ amino
acid sequences in UniProtKB. To ﬁnd protein properties, the authors
scanned the text for head nouns such as ‘‘activity’’ and ‘‘binding’’.
Tokens of the encompassing noun-phrases are stemmed and the
resulting phrase compared to terms in the Molecular Function
branch of the Gene Ontology. In addition, the authors searched
for impact directions, such as ‘‘increase’’, ‘‘abolish’’, and negations.
For the ﬁnal mapping of mutations to impacts, Laurila et al. [12]
employ a score measuring the sentence distance between a muta-
tion occurrence and an impact occurrence. Precision for grounding
mutations was given as 83% at 83% recall; the mapping of mutants
to impacts achieved 86% precision at 34% recall; evaluation was
performed on a corpus of 13 full text documents, with 54 unique
mutations and 73 unique mutant–impact relations.
Tari et al. studied the synthesis of drug-metabolic networks
(mapping each drug to its metabolizing enzymes) by extracting
these relations from the literature [14]. They parsed sentences with
a dependency parser, establishing syntactic dependencies between
enzymes and drugs mentioned together in a sentence. Using pre-
formulated queries against these syntactic structures, they search
for patterns like ‘‘DRUG  metabolized by  ENZYME’’, where the
wild-cards allow for certain dependencies connecting the parts,
for example, ‘‘predicate? object’’. Tari et al. populated a data-
base with about 13,000 PubMed abstracts, in their parsed form, so
Table 1
Numbers of entities found in 179,935 abstracts.
Totala Uniqueb Avg.c DrugBank/PharmGKBd
Genes/proteins 1,346,395 15,794 55 1018/3029
Drugs 277,258 1693 164 3797/646
Diseases 1,098,883 9539 101 –/705
Adverse effects 525,705 1414 372
Mutations 92,173 20,339 4
RefSNP 15,883 6208 2 –/1462
Alleles 52,732 1099 39
Populations 139,986 208 663
Frequencies 36,260
a Total number of occurrences, including duplicates, including entities with no
identiﬁer or canonical name.
b Unique entities include only those entities that were assigned to an identiﬁer or
canonical name, excluding duplicates; entities of the type ‘Frequencies’ (example:
‘‘8%’’) were not mapped to canonical names.
c Average number of occurrences of a particular identiﬁed entity; includes mul-
tiple occurrences of that entity per abstract, therefore the average number of
abstracts that discuss an entity is lower.
d Number of unique entities found in DrugBank and PharmGKB.
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tions. Their system achieves a precision of 92% for gene–drug rela-
tions, albeit estimated on a low number of predicted relations.
Coulet and colleagues built a semantic network of pharmacoge-
nomic relationships between genes, drugs, phenotypes, and entities
that are modiﬁed by the former, such as drug response [15]. Their
method employs dependency graphs obtained from the Stanford
Parser, representing the syntactical structure of a sentence [16].
Sentences that contained either one gene and one drug, or one gene
and one phenotype6, were retrieved from PubMed abstracts and then
parsed. The authors extracted all paths that link two entities using an
intermediary (possibly nominalized) verb and map each instance
onto an ontology of normalized pharmacogenomics relationships.
For instance, the phrase ‘‘differences in warfarin requirements’’ was
mapped to the concepts of drug (‘‘warfarin’’), dose (‘‘requirements’’),
and variation (‘‘differences’’), resulting in the overall notion of
‘‘warfarin dose variation’’. From these normalized relations, the
authors were able to build semantic networks surrounding entities
of interest to pharmacogenomics (such as individual genes).
1.2. Outline
The remainder of this paper is organized as follows. We start
with a description of our methods for named entity recognition
(Section 2.1), normalization Section 2.2, and relationship extraction
Section 2.3. In Section 3 we present statistics on the content of the
automatically ﬁlled repository SNPshot. We continue with an eval-
uation of our methods by comparing SNPshots content with data
from PharmGKB and DrugBank to estimate coverage; and by man-
ual inspection to obtain precision/recall values. Section 4 describes
the user interface and examples available at http://bioai4core.
fulton.asu.edu/snpshot. We conclude this paper with a discussion
in Section 5.2. Methods
2.1. Recognition of named entities
The entity types we are trying to ﬁnd are genes (incl. proteins,
enzymes), drugs, diseases, adverse drug reactions (ADRs), muta-
tions/SNPs, RefSNPs (rs-numbers), names of alleles, populations,
and frequencies, also listed in Table 1. For some of them, we con-
sider simple rule-based approaches to be sufﬁcient; for others,
we use dictionaries generated from relevant databases; for genes
and diseases, we train an off-the-shelf tagger as these names come
in too many variations, many of which will not be captured by dic-
tionary-matching. We will present the method for each entity type
in the following. Running named entity recognition for various
types in parallel will typically result in overlapping entities—a gene
name might contain or be equal to the name of a disease (‘‘breast
cancer associated gene 1’’, ‘‘Neuroﬁbromatosis 2’’), a gene name
might be identical to a drug (‘‘insulin’’), etc. In these cases, we
decided on a heuristic to replace drugs with genes, diseases with
genes, and genes with mutations for exact matches; we keep over-
lapping names as separate entities (‘‘breast cancer’’ within ‘‘breast
cancer associated gene 1’’).
2.1.1. Genes
For the recognition of gene names, we trained BANNER [17] on
the BioCreative II GM training set [18]. BANNER runs a 2nd-order
conditional random ﬁeld to assign a sequence of labels to a se-
quence of tokens (a sentence), where labels are in BIO-format:6 From a ﬁxed set of 41 genes, 3007 drugs, and 4204 phenotypes (diseases and
adverse reactions).‘‘not part of a gene name’’ (O), ‘‘inside of a gene name’’ (I), and
‘‘at the beginning of a gene name’’ (B). It uses feature classes such
as token surface, character bi- and tri-grams, preﬁxes, sufﬁxes,
part-of-speech tag, as well as features taken from a window sur-
rounding the current token. On the BioCreative II GM training
set, this results in a collection of about 1.5 million individual
features.
2.1.2. Genotypes: variants, mutations, SNPs, alleles, haplotypes
Although there have been recommendations for the description
of sequence variants [19],7 favoring the form ‘‘c.76A>T’’, they occur
in much more variations in free text. We use MutationFinder [13] as
a starting point, adding more variations frequently occurring in
PubMed abstracts (‘‘-3402C>T’’, ‘‘c.183 A>C’’), which we found
searching PubMed for related keywords (allele, mutation, gene,
etc.) and then manually enumerated all variations not yet covered.
We wrote additional components to also ﬁnd non-single nucleotide
variants (‘‘c.76_78delACT’’, ‘‘MV324KF’’) and insertions/deletions
(‘‘1707 del T’’, ‘‘c.76_77insG’’), RefSNP (rs) numbers, as well as names
of alleles/haplotypes (like in ‘‘CYP2D6*4’’ ‘‘T allele’’, ‘‘null allele’’,
‘‘GC/GC genotype’’). For simplicity, in the remainder we refer to vari-
ants, mutations, alleles, and haplotypes together as variants when
applicable.
2.1.3. Diseases and adverse drug reactions
To ﬁnd names referring to diseases, we pursue two strategies.
The ﬁrst uses BANNER, trained on a corpus with disease annota-
tions, consisting of about 3000 sentences8 [20]. As only about 10%
of the sentences in this corpus do not contain any disease, we added
200 random sentences from the BioCreative II GM training data. The
second strategy builds on a dictionary extracted from UMLS, consist-
ing of about 162 k terms for 54 k concepts from the six categories
‘‘Disease or Syndrome’’, ‘‘Neoplastic Process’’, ‘‘Congenital Abnormal-
ity’’, ‘‘Mental or Behavioral Dysfunction’’, ‘‘Experimental Model of
Disease’’, and ‘‘Acquired Abnormality’’. We manually went through
the list of names to remove unspeciﬁc or spurious disease names,
such as ‘‘symptoms’’, ‘‘disease’’, ‘‘disorder’’, ‘‘dependence’’, and ‘‘deﬁ-
ciency’’, as well as ‘‘endocrine’’, ‘‘cortex’’, ‘‘AA’’, and ‘‘dissociation’’.
This task was alleviated by sorting terms according to occurrence
frequency in a PubMed sample.
Our dictionary for adverse drug reactions originates from the
SIDER Side Effect Resource [21]. SIDER provides a mapping of7 HGVS—http://www.hgvs.org/mutnomen/recs.html.
8 AZDC—http://diego.asu.edu/downloads/AZDC.
Table 2
Numbers of relations found in 179,935 abstracts. Total numbers include duplicate
occurrences, in the same and across abstracts. Unique relations include only those in
which both entities could be assigned to an identiﬁer or to a canonical name.
Relations found in PharmGKB, including/excluding duplicates.
Total Unique PharmGKB
Gene–drug 191,054 31,593 6820/3014
Gene–disease 709,987 102,881 8147/4478
Drug–disease 117,834 26,268 4343/939
Drug–adverse effect 73,696 16,569
Gene–variant 101,477 21,704 645/516
Gene–allele 65,569 6802 146/99
Gene–RefSNP 12,881 5748 1820/1125
Allele–population 7181 1891
Variant–population 12,897 6765
Allele frequency 6,893 279
Variant frequency 6,646 1654
Population frequency 8404 144
Drugs–populations 12,849 4388
Drugs–alleles 6,778 1858
Drug–RefSNP 1,161 721
Drug–mutation 10,809 5491
Sum 1,315,811 233,964
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ADR’s synonym set based on the respective UMLS entry. The ﬁnal
dictionary has 1676 UMLS concepts with 6497 terms.
2.1.4. Drugs
The dictionary for drugs is based on DrugBank [22], containing
around 29,000 different drug names (incl. generic names, brand
names). As drugnamesdonot appear inmanyvariations – this holds
in particular for brand names – we can apply a case-insensitive but
otherwise exact matching. DrugBank cross-links with PharmGKB
and other resources, sowewere able to collect additional synonyms
and PharmGKB IDs, as well as PubChem Compound and Substance
identiﬁers to provide hyperlinks to additional information.
2.1.5. Populations and frequencies
We use close to 950 terms referring to ethnicities, regions,
countries and their inhabitants, mostly based on WikiPedia entries
for countries and ethnic groups, and match them (case insensitive)
against the text. Examples include ‘‘Caucasian’’, ‘‘Ashkenazi Jews’’,
‘‘Italian’’, ‘‘North African’’. Based on observations, we ﬁlter out
some occurrences in phrases such as ‘‘Chinese [hamster]’’ and
‘‘United States [Food and Drug Administration]’’. For frequencies,
we extract all numerals (decimal values from 0..1 and percentages,
including ranges such as ‘‘7–12%’’) from sentences that contain any
of the words ‘‘allele’’, ‘‘variant’’, ‘‘mutation’’, or ‘‘population’’. We
remove typical false positives, for example, referring to p-values,
odds ratios, and conﬁdence intervals, also using trigger words such
as ‘CI’, ‘OR’, and ‘p 6 . . .’.
2.2. Entity grounding and normalization
Names referring to genes, diseases, and drugs come in many
variations: ‘‘CYP2D6’’, ‘‘Cytochrome p450 2D6’’, ‘‘P450 IID6’’ all re-
fer to the same enzyme (EntrezGene ID 1565). Knowledge integra-
tion (collecting different facts on the same gene), evaluation
(compare our results to curated facts in databases), and search
(search within our collected information) all require to map each
occurrence to a unique identiﬁer, which is then used to refer to
the entity. To assign EntrezGene IDs to each individual gene, we
ran GNAT on the recognized genes [23], with the difference that
we limit the candidate genes to human, murine, and rat genes.
GNAT ﬁrst tries to normalize each gene name recognized by
BANNER, for instance, removing modiﬁers such as ‘‘wild-type’’ or
species and tissue from the beginning of a name, and others such
as ‘‘gene’’ and ‘‘isozyme’’ from the end. It then tries to match the
resulting name to a dictionary of gene names from EntrezGene
(here, restricted to the species human, mouse, and rat) to ﬁnd
candidate IDs for each gene name. In case of multiple candidates,
disambiguation ﬁrst considers the species, and then compares
the text surrounding the gene mention with the gene’s annotations
known from EntrezGene and UniProt: Gene Ontology terms, inter-
action partners, location and tissue speciﬁcity, functional descrip-
tions, etc., as obtained from EntrezGene and UniProt. This
comparison yields a score per gene and text, converted into a like-
lihood and used to rank candidate IDs accordingly.
Note that for our purposes, ‘‘genes’’ includes proteins/enzymes.
When we use dictionary-based approaches to ﬁnd drugs and dis-
eases/ADRs, the dictionaries explicitly link each match to an iden-
tiﬁer referring to the respective database (DrugBank, using DB and
PA accession codes; UMLS, using CUIs). In the case of diseases, we
match each mention found by BANNER to the dictionary to assign
an ID (case-insensitive, independent of token order). In case an ID
was found, we represent genes, drugs, and diseases/ADRs using an
ofﬁcial symbol or preferred term; in the remaining cases, we pick a
canonical term based on occurrence frequency, token surface (pre-ferring ‘‘Ocular Hypertension’’ over ‘‘ocular hypertension’’), and
length (preferring shorter terms).
Mentions of genetic variants, alleles, and populations are
grounded to canonical names in the following ways. For genetic
variants, we identify the position/range and the nucleotides/resi-
dues involved to map them to the format recommended by HGVS
[19], available for DNA, RNA, and amino acid sequences for muta-
tions, insertions, and deletions affecting single or multiple posi-
tions (ranges). We did not yet implement the recommendations
for repeats, inversions, conversions, and translocations, due to
the infrequent occurrences of either in our data. As canonical
names for alleles we use the star notation (‘*1’), and the genotype
(‘‘TT allele’’) or ﬁxed terms such as ‘‘null allele’’ and ‘‘variant allele’’
when no speciﬁc information is given. Mentions of populations are
mapped to a controlled vocabulary, to make orthographic and lex-
ical variations.2.3. Extraction of relations
Our system extracts twelve types of binary relations between
the aforementioned entities, as listed in Table 2. Driven by exam-
ples and preliminary evaluation, we decided on a list of seven
methods to extract relations. Whether a method gets applied de-
pends on (i) the relation type we are looking for (one of the afore-
mentioned list), (ii) the basic structure of the sentence, and (iii) if
another method was able to extract a relation beforehand. We start
with sentence-based co-occurrence, which yields good precision
for gene–drug, gene–disease, and drug–disease associations al-
ready, in particular when reﬁned by using relation-speciﬁc key-
words (see section on evaluation). For other types of relations,
co-occurrence does not yield sufﬁcient precision, and therefore
we implement additional extraction methods (detailed in the
following):
1. high conﬁdence co-occurrence that includes keywords,
2. co-occurrence without keywords,
3. 1:n co-occurrence,
4. enumerations with matching counts,
5. LCA sub-tree,
6. m:n co-occurrence,
7. low conﬁdence co-occurrence.
Based on results from manual evaluation of predictions, see
Section 3.4.1, we sorted these methods by descending expected
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ply methods 1–7, in this order, to each sentence that has entities of
the desired types; once one method extracted a relationship be-
tween two entities, we would stop there and not run any of the
downstream methods to check the same pair of entities again. To
each relationship we therefore assign a conﬁdence score that cor-
responds to the measured precision of the highest-ranking method
that could extract that relation. In the worst case, if methods 1–6
fail, we still extract a relation based on mere sentence-level co-
occurrence, but assign a low conﬁdence score.
(1) ‘‘High conﬁdence co-occurrence’’ refers to co-occurrence
that includes keywords referring to the type of relation.
We apply this strategy to gene–drug, gene–disease, drug–
ADR, drug–disease, and mutation–disease associations, and
use keywords from PolySearch [24] as well as our own.9
Every entity of one type is paired with every entity of another
type when they co-occur in the same sentence. ‘‘High conﬁ-
dence’’ results from our own estimates for these three types,
see our evaluation in Section 3, combined with previous
results [25,26]; also see Section 3.4.1 on manual evaluation.
(2) For allele–population and variant–population relationships,
we use sentence-level co-occurrence without keywords:9 Gaz‘‘The LRRK2 G2019S mutation is frequent in apparently spo-
radic PD in North Africans.’’We found only very few instances were such pairings where
invalid for these two relation types; and most of those were
negations. For some gene–drug, gene–disease, and drug–dis-
ease co-occurrences, no keyword was found in the sentence,
so they fall into this second category, giving lower conﬁdence
than ones found by the ﬁrst step.(3) For some types of associations, a relation between all possi-
ble pairs can be predicted when one of the entity types has
only a single instance in the given sentence, and the other
occurs one or more times, called 1:n co-occurrence here.
Genetic variants are an example: if a single gene is men-
tioned in a sentence, together with one or more mutations,
most likely all mutations mentioned in the same sentence
will refer to this gene. Note that ‘‘single instance’’ includes
repetitions of the same entity. Whenever we ﬁnd multiple
instances for both entity types, we would apply one of the
following methods (4)–(6). In many cases, in particular for
allele and variant frequencies in populations, associations
are discussed in either of the following way:
(4) Many associations occur as lists of entities of one type are
followed by lists of entities of the other type, with matching
counts. An example is the sentence‘‘The frequencies of CYP1B1*1, *2, *3, and *4 alleles were
0.087, 0.293, 0.444, and 0.175, respectively.’’Here, we assign the ﬁrst frequency mentioned to the ﬁrst
allele, the second to the second, and so on.(5) If the sentence consists of a list of associations, for instance,‘‘The allele frequencies were 18.3% (-24T) and 21.2%
(1249A)’’,0 For more information and discussion of a related task, please refer to Coulet et al.
5].
1 DrugBank ﬁles: all_enzyme_protein.fasta, all_target_protein.fasta; PharmGKB:we assign associations based on distance in the parse tree,
essentially preferring pairs of entities that occur in smaller
phrases. The Stanford parser [16] provides us with the gram-
matical structures of such sentences, represented as a tree.
The tree reﬂects dependencies between phrases, such as frometteers—http://bioai4core.fulton.asu.edu/snpshot/download/keywords.html.
lation
2 Pha
3 httpa verb to its subject, or from nouns to their modiﬁers10 Our
method utilizes the sub-trees of all lowest common ancestors
(LCAs) for all potential pairings (in the example above, each
potential allele–frequency pair) to subsequently pick the clos-
est pair and exclude those two entities from further pairings.
We settled on a maximum distance (edges in the sub-tree
connecting both leaf nodes) of ten that showed the best bal-
ance between precision and recall.(6) If none of the criteria for (3)–(5) apply, we build associations
between all pairs and call them ‘‘m:n co-occurrences’’. In
those, we have only an intermediate conﬁdence, since most
likely some predicted associations will be false.
(7) Finally, if all previous ﬁltering steps fail (that is, they do not
apply to the pair nor predict an association), we still store
each pair in the repository, but assign a low conﬁdence to
them.
In addition to relations extracted from sentences, we add ab-
stract-level co-occurrence for completeness. Such associations of-
ten provide useful hints on potential relations, although not
explicitly mentioned. All information derived in this way are
marked as such and appear in dedicated sections of SNPshot to
not get mixed with the more certain single sentence-based associ-
ations. We also require each abstract-level relation to occur in at
least ﬁve different abstracts in order to appear in SNPshot.3. Evaluation and results
3.1. Datasets
We ran two experiments to evaluate intrinsic performances of
our approach. (1) To estimate precision and recall of individual
extraction components (entity recognition and normalization,
relation extraction), we processed more than 3500 PubMed ab-
stracts found via PharmGKB relations and manually checked 2500
predictions. (2) To compare our extracted data to DrugBank and
PharmGKB11 to estimate coverage, we expanded the ﬁrst set in two
steps: (i) we collected all PubMed IDs annotated for genes important
for pharmacogenomics from PharmGKB (356 articles for 40
‘‘Annotated PGx genes’’)12 and fetched PubMed’s ‘‘Related Articles’’,
resulting in around 26,000 abstracts and (ii) we searched PubMed
with a query that returns abstract likely to discuss variants of human
genes together with drug responses and increased risk for disease:
(phenotype OR haplotype OR genotype OR mutation OR SNP.
OR variant OR allele OR polymorphism) AND (disease OR risk.
OR disorder OR malfunction) AND (drug OR bioavailability.
OR metabolize OR inhibit OR orally OR pharmacological).
AND human[MH] AND hasAbstract.
This query yielded more than 35,000 additional abstracts, for
each of which we then collected the top 20 related articles using
PubMed’s ELink utility.13 All in all, SNPshot currently contains
179,935 PubMed abstracts.3.2. Data in the SNPshot repository
Tables 1 and 2 summarize all entities and relations found in the
two datasets; Table 3 shows the number of relations per extractions.zip, variantAnnotations.zip.
rmGKB VIP genes—http://www.pharmgkb.org/search/annotatedGene/.
://eutils.ncbi.nlm.nih.gov/corehtml/query/static/elink_help.html.1
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Table 3
Numbers of relations found per method, including duplicates and non-identiﬁed
entities. See column ‘Total’ in Table 2 for types of relations. Mx refers to the respective
number for each method as discussed in Section 2.3.
Method Total number of relations
M1: Co-occ with keywords 890,828
M2: Simple co-occ 223,113
M3: Co-occ for 1:n 107,408
M7: Low conﬁdence co-occ 44,249
M6: Co-occ for m:n 28,655
M5: LCA sub-tree 19,343
M4: Enumerations 2215
Total 1,315,811
Table 4
Performance per entity type, as estimated by manual evaluation. The penultimate row
shows macro-averaged precision, recall, and f-score; the last row shows the
respective micro-averaged results. TP, true positive; FP, false positive; FN, false
negative; precision, recall, f-score in %.
Entity type TP FP FN Total P R F
Genes 509 54 40 603 90.4 92.7 91.5
Drugs 117 10 33 160 92.1 78.0 84.5
Diseases 283 32 13 328 89.8 95.6 92.6
Adverse effect – Evaluated with diseases –
Mutations 53 0 19 72 100.0 73.6 84.8
RefSNP 12 0 0 12 100.0 100.0 100.0
Alleles 102 5 13 120 95.3 88.7 91.9
Populations 30 0 7 37 100.0 81.1 89.6
Frequencies 28 0 0 28 100.0 100.0 100.0
Total 1134 101 125 1360 96.0 88.7 91.9
91.8 90.1 91.0
Table 5
Performance per type of relation, estimated by manual evaluation.
Relation type TP FP FN Total P R F
Gene–drug 136 39 18 199 77.7 88.3 82.7
Gene–disease 356 113 22 499 75.9 94.2 84.1
Drug–disease 42 8 15 65 84.0 73.7 78.5
Gene–variant 47 33 17 98 58.8 73.4 65.3
Gene–allele 111 45 12 170 71.2 90.2 79.6
Gene–RefSNP 11 6 0 17 64.7 100.0 78.6
Allele frequency 13 9 2 24 59.1 86.7 70.3
Variant frequency 2 2 0 4 50.0 100.0 66.7
Popul. frequency. 14 15 2 31 48.3 87.5 62.2
Variant–popul. 6 3 0 9 66.7 100.0 80.0
Allele–popul. 13 9 2 25 59.1 86.7 70.3
Total 751 282 90 1141 65.0 89.2 74.4
72.7 89.3 80.2
Table 6
Performance per method, estimated by manual evaluation.
Method TP FP Relations P
M1: Co-occ with keywords 500 147 651 77.3
M2: Simple co-occ 53 25 78 67.9
M4: Enumerations 2 0 2 100.0
M5: LCA sub-tree 32 7 39 82.1
M3: Co-occ for 1:n 125 61 186 67.2
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fulton.asu.edu/snpshot/Statistics. For comparison, Table 1 also
shows the numbers of unique entities contained in DrugBank and
PharmGKB, and Table 2 the relations in PharmGKB. DrugBank con-
tains 12,110 gene–drug relations: 1,039 enzyme–drug and 11,121
drug–target pairs. PharmGKB and DrugBank are manually curated,
so more precise information can be expected, but for a lower total
number of entities and relations; DrugBank also contains automat-
ically and non-approved relations, see Section 3.4.2.
Analyzing all 179,935 abstracts took around 180 h on an eight
core machine with 32 GB of RAM, where we split the data into
two batches of six chunks each. The largest proportion of time
went into deep parsing with the Stanford parser [16], and recogni-
tion and normalization of gene and disease names. We split ab-
stracts into sentences using the Julielab Sentence Boundary
Detector,14 resulting in 1,890,624 sentences.
3.3. Evaluation of entity recognition and normalization
For some components, performance was evaluated previously
on external data sets. BANNER’s performance yields an f-score of
86% for gene mention recognition, as evaluated on the BioCreative
2 GM test data. On the AZDC corpus for gene-disease associations
(see previous section), the disease recognition component yields
77% f-score. The gene name normalization component, GNAT, cur-
rently achieves 81% f-score. Narrowing down the task to identify
only genes of a single species, performance varies between 75%
and 89% in f-score, as evaluated on BioCreative 1 and 2 GN data;
GNAT achieves 85% for human genes, which were the focus of this
paper.
65% of the gene names could be mapped to an EntrezGene ID
(872 k out of 1346 k instances). 4% were either gene lists or protein
complexes that would require at least two IDs (‘‘CYP3A4/5’’) and
were not split properly by our method. The remaining 30% consist
of too unspeciﬁc gene mentions to assign an ID (for example, a
name of a gene family, ‘‘major histocompatibility complex’’), not
human, murine, or rat genes, or false positive gene mentions
(‘‘mutation’’, ‘‘q21’’).
3.4. Evaluation of relation extraction
As mentioned above, we performed two evaluations: the ﬁrst
resulted from manual inspection of predicted results; the second
evaluation was a comparison of our predictions to the data in
DrugBank and PharmGKB, yielding an estimate about coverage.
We present details on each evaluation and results next.
3.4.1. Manual evaluation
For the manual evaluation, we ran our system on 3614 abstracts
that were discussed with the 40 VIP genes of PharmGKB or associ-
M6: Co-occ for m:n 16 11 27 59.3
M7: Low conﬁdence co-occ 23 31 54 42.6
14 JSBD—https://www.julielab.de/Resources/Software/NLP+Tools.html.ated with these as determined by PubMed’s ‘‘Related articles’’
functionality (see Section 3.1 for details). Five annotators (LT, JH,
SL, NV, DV) annotated sentences that had at least one predicted
relation, by marking true positive, false positive, and adding false
negative entities as well as relations (of all types considered in this
paper). Note that this manual annotation covered only sentences
for which at least one relation (of any type) was predicted already:
our aim was mostly to get an understanding of expected precision,
which we then use to assign conﬁdence scores to each relation in
our database. All predictions were sorted by sentence, to get a bal-
anced assortment of entities and relations. Tables 4–6 show the
performances for extracted entities, extracted relations, and per
relation extraction method, respectively. From the manual evalua-
tion, we see that most entities can be found with a high precision,
especially the types allele, population, frequency, and mutation.
For genes, drugs, and diseases, precision lies between 89% and
92%; here, we note that the system often marks diseases also as ad-
verse effects, so precision for ADRs is low. F-scores for all entities
range from 85% to 92% for entity types with reasonable numbers
of occurrences. For relations, f-score is between 62 and 84%. Here,
Table 7
Comparison of relations in PharmGKB to the results automatically extracted from
179,935 PubMed abstracts. TP: true positives (found in SNPshot and PharmGKB), FN:
false negatives (not found in SNPshot).
Relation type Coverage (%) TP FN
Gene–drug 93.7 2946 199
Gene–disease 94.7 4683 260
Drug–disease 78.0 981 276
Gene–variant 96.5 505 18
Gene–allele 100.0 100 0
Gene–RefSNP 65.4 744 394
848 J. Hakenberg et al. / Journal of Biomedical Informatics 45 (2012) 842–850surprisingly, relations between ‘‘complex’’ entities (where NER is
concerned) score higher than relations involving the simple types.
This can in part be explained by the keyword-ﬁltering we use for
gene–drug, gene–disease, and drug–disease relations. These num-
bers also point out that co-occurrence can still be considered a pre-
cise (and not only high recall) baseline technique for extracting
certain types of relations, which concurs with ﬁndings by others.
Chun et al. [25] found that associations of genes with diseases
can be predicted with 94% precision using sentence co-occurrence.
This holds under the assumption that both entities are extracted
correctly by named entity recognition. Chang and Altman [26] esti-
mated a precision of 70% for gene-drug co-occurrence based on
100 predicted pairs. Note that for other types of relations, such
as protein–protein interactions, co-occurrence yields less than
50% precision. In SNPshot, entity extraction is aided by entity nor-
malization, namely mapping each entity to a database identiﬁer
(EntrezGene ID, DrugBank ID, etc.), which further increases conﬁ-
dence in individual entities as well as relations if a mapping could
be found.Fig. 1. Excerpt from the data sheet for the human epidermal growth factor receptor, EGF
and examples for a genetic variant and disease association. View the entire entry at htt3.4.2. Automated evaluation—comparison to DrugBank and
PharmGKB
Comparing our predictions based on around 180,000 PubMed
abstracts to DrugBank [22] and PharmGKB [5], we can estimate a
coverage provided by our method. This enables us to tell how
many relations currently stored in DrugBank and PharmGKB can
be extracted from PubMed, with conﬁdences per relation type
and method as discussed in the previous section. Note that we
are not able to properly estimate precision using this method: for
a relation predicted by our method that is not contained in either
DrugBank or PharmGKB, we cannot automatically decide whether
the relation is a false positive, or just not yet contained in either
database. In addition, about 50% of the drug targets in DrugBank
are not approved and many of them likely false positives; they
were predicted by the PolySearch engine based on sentence-level
co-occurrence [cmp. 22,Table 1]. We therefore also presented the
manual evaluation in the previous section.
For the automated comparison, we considered all relations in
the two databases for which a unique identiﬁer or canonical name
was available for each partner in the sought relation. Table 7 lists
coverages for the types of relations found in the PharmGKB knowl-
edge base. Based on 180,000 PubMed abstracts, SNPshot contains
almost 94% of the gene–drug relations in PharmGKB. We found
the highest coverage with gene–variant annotations in PharmGKB
(96.5%), and the lowest for genes mapped to rs-numbers (65.4%),
which could be explained by the low number of total relations of
this kind in SNPshot (compare Table 2). Comparing SNPshot with
DrugBank, we found that SNPshot can recover 91% of the en-
zyme–metabolite and drug–target relations in DrugBank; but note
that many of the drug–gene relations in DrugBank are also auto-
matically extracted and not approved.R, showing a summary of information on the gene, lists of predicted related entities,
p://bioai4core.fulton.asu.edu/snpshot/FactSheet?id=1956&type=GENE.
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SNPshot is available at http://bioai4core.fulton.asu.edu/snpshot.
Users can search the interface by gene, drug, disease, mutation, ad-
verse reaction, RefSNP number, allele, population, Entrez Gene ID,
DrugBank accession code, PharmGKB ID, and PubChem Substance
and Compound IDs. SNPshot shows a ‘‘Fact sheet’’ reﬂecting all
extracted relations concerning this entity. All facts are linked to
DrugBank and PharmGKB when possible, and backed up by evi-
dence sentences, shown together with sentences that contain
related information from the same source. SNPshot thus provides
a quick overview over genetic variations, implicated in drug
response and/or diseases. The fact sheets, when searched by drugs,
can help guiding clinical decisions or research questions by ﬁrst
scanning the literature available on the topic in a condensed man-
ner. They provide a quick overview of how genetic variants affect
the drug response of individual patients. We also envision that
SNPshot could ﬁrst be searched based on populations (that is, for
race/ethnicity of the patient), even before genetic ﬁnger-printing
takes place, to ﬁrst estimate the likelihood that the patient might
carry the suspicious allele. Fig. 1 shows an exemplary repository
entry for the EGFR gene, together with two drugs.
For summaries and to download and copy-and-paste informa-
tion, two additional views are also available from each ‘‘Fact sheet’’;
one displays a tabular summary of all related entities, the other
returns a tab-separated ﬁle. Downloads from SNPshot data can also
be triggered by parameterized HTTP requests. For instance, the
request http://QuickOverview?id=6557&type=GENE&rettype=tsv
will fetch all information on the gene SLC12A1 (EntrezGene ID
6557) in a tab-separated form. More information on formats and
parameters are available in the ‘‘About’’ section of the website.5. Discussion and conclusions
In this paper, we presented automated methods to populate a
repository, called SNPshot, related to genetic variants and their
associations with drugs and diseases. SNPshot links facts covering
genes, variants/mutations, alleles, frequencies, and populations,
with drug and disease/adverse reactions data. It can be used to
guide decision processes in personalized medicine, linking drug
treatments to known impacts of ‘‘non-wild-type’’ enzymatic activ-
ity. SNPshot indexes around 180,000 abstracts from PubMed and
thus allows to quickly search and browse these types of informa-
tion, in addition to manually curated databases such as PharmGKB
and DrugBank. It can also function as an aid to populate these re-
nowned collections.
Based on the results from manual evaluation, we assigned con-
ﬁdence values to each method per relation type, which are re-
ﬂected in the repository to indicate how certain each predicted
association is. This allows to sort the repository by certainty, to
ﬁrst use relations that are more likely to be correct for further anal-
ysis, annotation, or integration. Due to the limited size of our man-
ual evaluation, it has to be noted that conﬁdence scores for the
more prevalent relation types, such as gene–drug and gene–allele,
are more reliable than others, including variants in populations.
From the larger-scale automated comparison against other dat-
abases, we found that SNPshot covers between 65% (RefSNPs
mapped to genes) and 95% (genes associated with diseases) of
the relations in PharmGKB, based on 180,000 PubMed abstracts.
For certain types of relations, the coverage reaches 100%, but the
number of relations to compare with is too low to draw deﬁnite
conclusions (such as for the 100 gene to allele mappings). Regard-
ing gene–drug associations, we were able to recover 91% of the
data in DrugBank, and 94% of PharmGKB. Starting with 31,000 un-
ique gene–drug associations (enzyme-drug or drug-target), andtaking into account false positive rates for genes and drugs (around
10% each) and gene–drug relations (25%), there are more than
10,000 potentially relevant gene–drug associations left in SNPshot
that are yet to be (hand-) curated in other databases. SNPshot can
thus suggest those for curation, and we are looking into mecha-
nisms for ranking entities and associations for novelty, coverage
in databases, and relevance to disease, and relevance to pharmaco-
kinetics and -dynamics.
We seek to further integrate our data with facts known about
the ‘‘druggable genome’’ [27], to better identify potential drug tar-
gets and annotate known targets with variants. Comparing the
data in SNPshot to DrugBank reveals that our selection procedure
to ﬁnd relevant PubMed abstracts focuses more on drug–metabo-
lizing enzymes than a larger number of known drug targets, which
we want to address in the future. We categorize each gene accord-
ing to its Gene Ontology annotations, searching for the closes par-
ent in the GO hierarchy that is either ‘‘metabolic process’,
‘‘transporter activity’’, ‘‘ion channel activity’’, ‘‘receptor activity’’,
or ‘‘other’’. This helps in identifying the potential role of the gene
product, by also looking for corresponding evidence in the sen-
tence a gene–drug relation was found in.
For future work we envision mapping of gene/disease entities
and relations to OMIM, and further integration with PharmGKB
and SIDER. Following Chang and Altman [26], it would be valuable
to automatically assign evidences to categories such as Clinical
outcome, Pharmacokinetics, and Genotype (already used in Phar-
mGKB) to ‘‘enhance retrieval and stimulate hypothesis genera-
tion’’ [26]. GeneOntology employs a system of evidence codes,
ranging from Author statement and Automatically assigned evidence
to Experimental evidence codes, and we want to add similar anno-
tations to SNPshot relations based on the respective source of
information to reﬂect reliability. Precision for named entity recog-
nition, grounding, and normalization is high (above 90%) for all
entities expect for adverse drug reactions, which were often con-
fused by the system with diseases, as these overlap to a large ex-
tent. Adding supervised classiﬁcation on top of recognition of
disease and ADR mentions to disambiguate between these two
classes is one of the next steps under development, since training
data is now becoming available through in-house evaluation and
external user input. As next steps concerning types of information,
we want to concentrate on adding data on cell lines and addi-
tional kinds of phenotypes, including gene expression and RNA
interference. In the same way that we categorize proteins, see
above, it will be useful to include drug classes, such as antipsy-
chotics and steroids, in the displayed information as well as allow
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